First Analysis
http://www.firstanalysis.com/index.asp?PID=16First Analysis is an investment organization specializing in private equity, venture capital, investment banking, and equity research. The sectors in the firm’s coverage universe include outsourced services, IT products and services, and chemistry-enabled businesses. First Analysis was founded in 1981.
View Older Stories View More Recent Stories
-
First Analysis Downgrades Box, Inc. (BOX) to Neutral
-
Repligen (RGEN) PT Raised to $107 at First Analysis
-
Paragon Biosciences Announces the Formation of Paragon Health Capital
-
First Analysis Downgrades Quotient Technology (QUOT) to Outperform
-
First Analysis Downgrades New Relic (NEWR) to Neutral
-
First Analysis Upgrades eHealth (EHTH) to Strong Buy
-
First Analysis Starts Avalara (AVLR) at Strong Buy (Friday)
-
UPDATE: First Analysis Upgrades Anika Therapeutics (ANIK) to Strong Buy
-
First Analysis Upgrades LeMaitre Vascular (LMAT) to Outperform
-
Middlemarch Partners Expands its Geographic Reach and Adds New Partners
-
Repligen (RGEN) Prices Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024
-
Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024
-
SynergySuite Closes $6 Million Series A Led by First Analysis
-
First Analysis Downgrades Tableau Software (DATA) to Neutral Following Acquisition
-
Deep Cuts in Northwest Carbon Emissions Achievable and Affordable
-
New Anthem Public Policy Institute Report Outlines Key Differences in How Individuals and the Public Perceive Social Determinants of Health
-
First Analysis Upgrades LiveRamp Holdings Inc. (RAMP) to Outperform
-
FRESH Study Results Demonstrates Fluid Responsiveness Is Dynamic During 72-Hour Sepsis Monitoring Window
-
First Analysis Downgrades ChannelAdvisor (ECOM) to Outperform
-
First Analysis Downgrades Alarm.com (ALRM) to Outperform
-
Lilly (LLY) Says Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and Effect of Lasmiditan in Patients with Prior Triptan Experience
-
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
-
First Analysis Downgrades Cambrex Corporation (CBM) to Outperform
-
First Analysis Upgrades SPS Commerce (SPSC) to Outperform
-
First Analysis Downgrades Advanced Disposal Services (ADSW) to Neutral Following Acquisition
-
New Data Show Encouraging Economic Outcomes for Medtronic HeartWare(TM) HVAD(TM) System
-
Two Abstracts by The Center for Innovative GYN Care Selected for Presentation at the 2019 Society of Gynecologic Surgeons Annual Meeting
-
Benefitfocus Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Secondary Offering
-
Benefitfocus Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Secondary Offering
-
Electric Vehicles Could Lower Power Bills For All Illinois Residents, New Study Finds
-
AppDetex Secures $10 Million in Series B Funding to Fuel Growth
-
First Analysis Upgrades Tabula Rasa Healthcare (TRHC) to Strong Buy
-
Pluralsight (PS) Prices 13.558M Share Follow-Offering by Selling Shareholders at $29.25/Sh
-
Pluralsight, Inc. Announces Pricing of Follow-On Offering by Selling Stockholders
-
Pluralsight, Inc. Announces Pricing of Follow-On Offering by Selling Stockholders
-
Tabula Rasa HealthCare (TRHC) Reports Acquisition of PrescribeWellness
-
Tabula Rasa HealthCare Announces Acquisition of PrescribeWellness Expanding its Medication Risk Mitigation Offering
-
Tabula Rasa HealthCare Announces Acquisition of PrescribeWellness Expanding its Medication Risk Mitigation Offering
-
Pluralsight (PS) Announces Proposed 13.56M Share Follow-On Offering by Selling Stockholders
-
Pluralsight, Inc. Announces Proposed Follow-On Offering by Selling Stockholders
-
Pluralsight, Inc. Announces Proposed Follow-On Offering by Selling Stockholders
-
Benefitfocus (BNFT) Prices 5.7M Secondary Offering of Common Stock at $48.25/Share
-
Benefitfocus Announces Pricing of Secondary Offering
-
Benefitfocus Announces Pricing of Secondary Offering
-
First Analysis Downgrades ORBCOMM (ORBC) to Outperform
-
Benefitfocus (BNFT) Announces 5.7M Share Secondary Offering of Common Stock
-
Benefitfocus Announces Secondary Offering
-
Benefitfocus Announces Secondary Offering
-
First Analysis Downgrades Sierra Wireless (SWIR) to Neutral
-
First Analysis Upgrades Fortinet (FTNT) to Outperform

